Decorin, a small leucine-rich proteoglycan, is considered an attractive candidate to inhibit prostate cancer tumorigenesis and bone metastases since decorin protein has been demonstrated to target multiple signaling pathways associated with prostate cancer tumorigenesis and bone metastases, including the WNT/β-catenin signaling pathway. Here, DCN is linked to prostate carcinoma.